Family case of cystic fibrosis

Cystic fibrosis is an autosomal recessively inherited monogenic disease caused by a mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, located on the long arm of chromosome 7 (7q31.2). This mutation results in a disruption in the transport of sodium and chloride ions between intercellular fluid and the epithelial cells of the excretory ducts of the exocrine glands. This paper presents the description of a family case of cystic fibrosis involving two patients who have been under observation since birth and are sisters (patient A – 4 years 10 months, patient B – 1 year 11 months). In both patients, neonatal screening and sequential diagnosis of cystic fibrosis identified the DF508/CFTRdele2.3(21kb) mutation, the most prevalent among the Caucasian population in the Russian Federation. The primary concern in managing both patients is the correction of nutritional status and minimization of exacerbations of chronic bronchopulmonary inflammation. To determine the management strategy for these patients, a consultation was held with Dr. E.I. Kondratyeva, a leading cystic fibrosis expert and professor at the MGSC Institute, who serves as the head of the Scientific and Clinical Department of Cystic Fibrosis and the Department of Genetics of Respiratory System Diseases, an expert of the European Society for Cystic Fibrosis Committee on Diagnostics and Registry, and Deputy Chief for Scientific Work of Research Clinical Institute of Childhood of the Ministry of Health of the Moscow Region. The peculiarity of the presented clinical cases lies in the fact that within one family, with an interval of 3 years, two girls with severe disease were born. Early diagnosis was performed for both, which has allowed for the slowing down of the pathology's progression.

1. [Resolution of the Government of the Russian Federation of 29.11.2022 N 2161 «On Amendments to the State Program of the Russian Federation «Health Care Development»] (in Russian). Available at: https://www.consultant.ru/document/cons_doc_LAW_432913/

2. Chagay N.B., Khayt G.Ya., Vdovina T.M., Shaforost A.A. [Cystic fibrosis being a polyendocrine disease (review)]. Problemy Endokrinologii = Problems of Endocrinology 2021; 67(2): 28–39 (in Russian). https://doi.org/10.14341/probl12694

3. Amelina Ye.L., Krasovskiy S.A., Shumkova G.L., Krylova N.A. [Тargeted therapy for cf patients with f508del/f508del genotype]. Pul'monologiya = Russian Pulmonology 2019; 29(2): 235–238 (in Russian). https://doi.org/10.18093/0869-0189-2019-29-2-235-238

4. Kondrat'yeva YE.I., Voronkova A.YU., Kashirskaya N.YU., Krasovskiy S.A., Starinova M.A., Amelina YE.L., Avdeyev S.N., Kutsev S.I. [Russian registry of patients with cystic fibrosis: lessons and perspectives]. Pul'monologiya = Russian Pulmonology 2023; 33(2): 171–181 (in Russian). https://doi.org/10.18093/0869-0189-2023-33-2-171-181

5. [Clinical guidelines for cystic fibrosis (Cystic fibrosis) 2021] (in Russian). Available at: https://www.consultant.ru/document/cons_doc_LAW_394787/8efd5f17af55cb35a770f73937590c642437b7eb/

6. [Order of the Government of the Russian Federation No. 3731-r dated December 5, 2022. «On Approval of the List of Specialized Therapeutic Nutrition Products for Disabled Children for 2023»] (in Russian). Available at: https://www.consultant.ru/document/cons_doc_LAW_433653/f62ee45faefd8e2a11d6d88941ac66824f848bc2/